Dopaminergic	O
Modulation	O
of	O
Effort	O
-	O
Related	O
Choice	O
Behavior	O
as	O
Assessed	O
by	O
a	O
Progressive	O
Ratio	O
Chow	O
Feeding	O
Choice	O
Task	O
:	O
Pharmacological	O
Studies	O
and	O
the	O
Role	O
of	O
Individual	O
Differences	O

Competing	O
Interests	O
:	O
J	O
.	O

Salamone	O
'	O
s	O
work	O
was	O
funded	O
by	O
the	O
NIH	O
(	O
NIMH	O
)	O
and	O
NIH	O
(	O
NIDA	O
),	O
and	O
he	O
has	O
received	O
compensation	O
from	O
Merck	O
-	O
Seronno	O
,	O
Pfizer	O
and	O
Roche	O
.	O

A	O
.	O

Makriyannis	O
was	O
supported	O
by	O
NIH	O
(	O
NIDA	O
).	O

C	O
.	O

Müller	O
received	O
funding	O
by	O
UCB	O
Pharma	O
within	O
the	O
Biopharma	O
collaborative	O
project	O
Neuroallianz	O
funded	O
by	O
the	O
German	O
Federal	O
Ministry	O
of	O
Education	O
and	O
Research	O
(	O
BMBF	O
).	O

M	O
.	O

Correa	O
received	O
funding	O
by	O
Fundació	O
Bancaixa	O
-	O
UJI	O
(	O
P1	O
.	O
1B2010	O
-	O
43	O
).	O

M	O
.	O

Pardo	O
was	O
supported	O
by	O
Fundació	O
Bancaixa	O
-	O
UJI	O
(	O
PREDOC	O
-	O
2007	O
-	O
43	O
),	O
and	O
L	O
.	O

López	O
-	O
Cruz	O
was	O
supported	O
by	O
Ministerio	O
Educación	O
,	O
FPU	O
(	O
AP2010	O
-	O
3793	O
).	O

None	O
of	O
the	O
other	O
authors	O
had	O
financial	O
interests	O
to	O
disclose	O
.	O

This	O
does	O
not	O
alter	O
the	O
authors	O
'	O
adherence	O
to	O
all	O
the	O
PLOS	O
ONE	O
policies	O
on	O
sharing	O
data	O
and	O
materials	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
PAR	O
MP	O
EN	O
MC	O
JDS	O
.	O

Performed	O
the	O
experiments	O
:	O
PAR	O
EJN	O
MP	O
LLC	O
MC	O
.	O

Analyzed	O
the	O
data	O
:	O
PAR	O
MP	O
LLC	O
EJN	O
MC	O
JDS	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
VKV	O
AM	O
YB	O
CEM	O
.	O

Wrote	O
the	O
paper	O
:	O
PAR	O
MP	O
MC	O
JDS	O
.	O

Mesolimbic	O
dopamine	O
(	O
DA	O
)	O
is	O
involved	O
in	O
behavioral	O
activation	O
and	O
effort	O
-	O
related	O
processes	O
.	O

Rats	B-OG
with	O
impaired	O
DA	O
transmission	O
reallocate	O
their	O
instrumental	O
behavior	O
away	O
from	O
food	O
-	O
reinforced	O
tasks	O
with	O
high	O
response	O
requirements	O
,	O
and	O
instead	O
select	O
less	O
effortful	O
food	O
-	O
seeking	O
behaviors	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
several	O
drug	O
treatments	O
were	O
assessed	O
using	O
a	O
progressive	O
ratio	O
(	O
PROG	O
)/	O
chow	O
feeding	O
concurrent	O
choice	O
task	O
.	O

With	O
this	O
task	O
,	O
rats	B-OG
can	O
lever	O
press	O
on	O
a	O
PROG	O
schedule	O
reinforced	O
by	O
a	O
preferred	O
high	O
-	O
carbohydrate	O
food	O
pellet	O
,	O
or	O
alternatively	O
approach	O
and	O
consume	O
the	O
less	O
-	O
preferred	O
but	O
concurrently	O
available	O
laboratory	O
chow	O
.	O

Rats	B-OG
pass	O
through	O
each	O
ratio	O
level	O
15	O
times	O
,	O
after	O
which	O
the	O
ratio	O
requirement	O
is	O
incremented	O
by	O
one	O
additional	O
response	O
.	O

The	O
DA	O
D2	B-GP
antagonist	O
haloperidol	O
(	O
0	O
.	O
025	O
–	O
0	O
.	O
1	O
mg	O
/	O
kg	O
)	O
reduced	O
number	O
of	O
lever	O
presses	O
and	O
highest	O
ratio	O
achieved	O
but	O
did	O
not	O
reduce	O
chow	O
intake	O
.	O

In	O
contrast	O
,	O
the	O
adenosine	B-GP
A2A	I-GP
antagonist	O
MSX	O
-	O
3	O
increased	O
lever	O
presses	O
and	O
highest	O
ratio	O
achieved	O
,	O
but	O
decreased	O
chow	O
consumption	O
.	O

The	O
cannabinoid	O
CB1	B-GP
inverse	O
agonist	O
and	O
putative	O
appetite	O
suppressant	O
AM251	O
decreased	O
lever	O
presses	O
,	O
highest	O
ratio	O
achieved	O
,	O
and	O
chow	O
intake	O
;	O
this	O
effect	O
was	O
similar	O
to	O
that	O
produced	O
by	O
pre	O
-	O
feeding	O
.	O

Furthermore	O
,	O
DA	O
-	O
related	O
signal	O
transduction	O
activity	O
(	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
)	O
was	O
greater	O
in	O
nucleus	O
accumbens	O
core	O
of	O
high	O
responders	O
(	O
rats	B-OG
with	O
high	O
lever	O
pressing	O
output	O
)	O
compared	O
to	O
low	O
responders	O
.	O

Thus	O
,	O
the	O
effects	O
of	O
DA	O
antagonism	O
differed	O
greatly	O
from	O
those	O
produced	O
by	O
pre	O
-	O
feeding	O
or	O
reduced	O
CB1	B-GP
transmission	O
,	O
and	O
it	O
appears	O
unlikely	O
that	O
haloperidol	O
reduces	O
PROG	O
responding	O
because	O
of	O
a	O
general	O
reduction	O
in	O
primary	O
food	O
motivation	O
or	O
the	O
unconditioned	O
reinforcing	O
properties	O
of	O
food	O
.	O

Furthermore	O
,	O
accumbens	O
core	O
signal	O
transduction	O
activity	O
is	O
related	O
to	O
individual	O
differences	O
in	O
work	O
output	O
.	O

Introduction	O

Brain	O
dopamine	O
(	O
DA	O
),	O
particularly	O
in	O
nucleus	O
accumbens	O
,	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
aspects	O
of	O
instrumental	O
behavior	O
[	O
1	O
]–[	O
4	O
].	O

Accumbens	O
DA	O
is	O
involved	O
in	O
approach	O
behavior	O
,	O
activational	O
aspects	O
of	O
motivation	O
(	O
e	O
.	O
g	O
.	O
vigor	O
,	O
persistence	O
),	O
and	O
enabling	O
organisms	O
to	O
overcome	O
work	O
-	O
related	O
response	O
costs	O
to	O
gain	O
access	O
to	O
significant	O
stimuli	O
[	O
1	O
]–[	O
13	O
].	O

The	O
increased	O
activity	O
induced	O
by	O
scheduled	O
presentation	O
of	O
food	O
pellets	O
is	O
accompanied	O
by	O
increases	O
in	O
accumbens	O
DA	O
release	O
,	O
and	O
is	O
reduced	O
by	O
DA	O
antagonism	O
and	O
accumbens	O
DA	O
depletions	O
[	O
5	O
],	O
[	O
14	O
].	O

Rats	B-OG
with	O
accumbens	O
DA	O
depletions	O
are	O
very	O
sensitive	O
to	O
ratio	O
requirements	O
in	O
operant	O
schedules	O
[	O
15	O
]–[	O
17	O
].	O

Moreover	O
,	O
DA	O
antagonism	O
or	O
interference	O
with	O
accumbens	O
DA	O
transmission	O
alters	O
response	O
allocation	O
in	O
tasks	O
that	O
measure	O
effort	O
-	O
related	O
choice	O
behavior	O
[	O
1	O
],	O
[	O
2	O
],	O
[	O
6	O
],	O
[	O
7	O
].	O

Several	O
behavioral	O
tasks	O
have	O
been	O
used	O
to	O
investigate	O
the	O
role	O
of	O
DA	O
in	O
effort	O
-	O
related	O
choice	O
.	O

Some	O
studies	O
have	O
used	O
a	O
T	O
-	O
maze	O
barrier	O
choice	O
task	O
,	O
and	O
reported	O
that	O
interference	O
with	O
DA	O
transmission	O
decreased	O
barrier	O
climbing	O
to	O
gain	O
access	O
to	O
a	O
high	O
magnitude	O
of	O
reinforcement	O
[	O
12	O
],	O
[	O
18	O
]–[	O
22	O
].	O

T	O
-	O
maze	O
and	O
lever	O
pressing	O
versions	O
of	O
effort	O
discounting	O
procedures	O
also	O
have	O
demonstrated	O
that	O
DA	O
antagonism	O
shifts	O
choice	O
behavior	O
of	O
rats	B-OG
towards	O
low	O
effort	O
alternatives	O
[	O
23	O
],	O
[	O
24	O
].	O

Another	O
task	O
that	O
has	O
been	O
used	O
is	O
the	O
concurrent	O
fixed	O
-	O
ratio	O
5	O
(	O
FR5	O
)/	O
chow	O
feeding	O
procedure	O
,	O
in	O
which	O
rats	B-OG
can	O
either	O
lever	O
press	O
on	O
a	O
FR5	O
schedule	O
for	O
preferred	O
high	O
-	O
carbohydrate	O
food	O
pellets	O
,	O
or	O
approach	O
and	O
consume	O
less	O
-	O
preferred	O
rodent	B-OG
chow	O
that	O
is	O
freely	O
available	O
in	O
the	O
chamber	O
[	O
1	O
],	O
[	O
6	O
],	O
[	O
25	O
].	O

Under	O
baseline	O
conditions	O
,	O
rats	B-OG
tested	O
with	O
this	O
procedure	O
typically	O
obtain	O
most	O
of	O
their	O
food	O
by	O
lever	O
pressing	O
while	O
consuming	O
very	O
little	O
of	O
the	O
chow	O
.	O

Systemic	O
or	O
intra	O
-	O
accumbens	O
administration	O
of	O
DA	O
antagonists	O
and	O
accumbens	O
DA	O
depletions	O
shift	O
response	O
allocation	O
such	O
that	O
lever	O
pressing	O
is	O
decreased	O
but	O
chow	O
intake	O
is	O
substantially	O
increased	O
[	O
6	O
],	O
[	O
25	O
]–[	O
31	O
].	O

This	O
effect	O
is	O
not	O
due	O
to	O
drug	O
-	O
induced	O
changes	O
in	O
food	O
preference	O
or	O
consumption	O
[	O
6	O
],	O
[	O
28	O
].	O

Moreover	O
,	O
the	O
effects	O
induced	O
by	O
DA	O
antagonism	O
or	O
depletion	O
differ	O
substantially	O
from	O
those	O
seen	O
following	O
pre	O
-	O
feeding	O
[	O
6	O
]	O
or	O
treatment	O
with	O
appetite	O
suppressant	O
drugs	O
such	O
as	O
fenfluramine	O
[	O
25	O
]	O
or	O
cannabinoid	O
CB1	B-GP
antagonism	O
[	O
30	O
];	O
these	O
appetite	O
-	O
related	O
manipulations	O
failed	O
to	O
increase	O
chow	O
intake	O
at	O
doses	O
that	O
suppress	O
lever	O
pressing	O
.	O

In	O
addition	O
to	O
accumbens	O
DA	O
,	O
there	O
is	O
a	O
body	O
of	O
research	O
implicating	O
adenosine	O
in	O
behavioral	O
activation	O
and	O
effort	O
-	O
related	O
processes	O
[	O
32	O
]-[	O
34	O
].	O

Adenosine	B-GP
A2A	I-GP
receptors	I-GP
are	O
primarily	O
localized	O
in	O
striatal	O
areas	O
,	O
including	O
both	O
neostriatum	O
and	O
accumbens	O
[	O
35	O
],	O
[	O
36	O
].	O

Furthermore	O
,	O
there	O
is	O
a	O
functional	O
interaction	O
between	O
DA	O
D2	B-GP
and	O
adenosine	B-GP
A2A	I-GP
receptors	I-GP
[	O
37	O
]–[	O
39	O
].	O

Intra	O
-	O
accumbens	O
injections	O
of	O
the	O
adenosine	B-GP
A2A	I-GP
agonist	O
CGS	O
21680	O
decreased	O
lever	O
pressing	O
on	O
a	O
ratio	O
schedule	O
[	O
34	O
],	O
and	O
also	O
produced	O
changes	O
in	O
effort	O
-	O
related	O
choice	O
behavior	O
similar	O
to	O
the	O
effects	O
of	O
DA	O
antagonism	O
[	O
33	O
].	O

In	O
contrast	O
,	O
adenosine	B-GP
A2A	I-GP
antagonists	O
have	O
been	O
shown	O
to	O
increase	O
fixed	O
interval	O
response	O
rate	O
[	O
40	O
].	O

Furthermore	O
,	O
several	O
studies	O
have	O
shown	O
that	O
adenosine	B-GP
A2A	I-GP
antagonists	O
can	O
reverse	O
the	O
effects	O
of	O
DA	O
D2	B-GP
antagonists	O
on	O
tests	O
of	O
effort	O
-	O
related	O
choice	O
behavior	O
[	O
21	O
],	O
[	O
22	O
],	O
[	O
31	O
],	O
[	O
32	O
],	O
[	O
41	O
],	O
[	O
42	O
].	O

The	O
present	O
studies	O
employed	O
a	O
variant	O
of	O
the	O
lever	O
pressing	O
/	O
chow	O
intake	O
choice	O
procedure	O
,	O
which	O
utilized	O
a	O
progressive	O
ratio	O
(	O
PROG	O
)	O
work	O
requirement	O
(	O
see	O
also	O
refs	O
.	O
[	O
13	O
],	O
[	O
43	O
]).	O

Similar	O
to	O
the	O
FR5	O
/	O
chow	O
feeding	O
choice	O
task	O
,	O
rats	B-OG
tested	O
with	O
this	O
PROG	O
/	O
chow	O
feeding	O
procedure	O
have	O
the	O
choice	O
of	O
pressing	O
the	O
lever	O
reinforced	O
by	O
presentation	O
of	O
the	O
more	O
preferred	O
pellets	O
vs	O
.	O
approaching	O
and	O
consuming	O
the	O
less	O
preferred	O
chow	O
;	O
the	O
difference	O
is	O
that	O
a	O
PROG	O
schedule	O
,	O
which	O
gradually	O
increases	O
the	O
ratio	O
requirement	O
,	O
is	O
used	O
instead	O
of	O
an	O
FR5	O
.	O

This	O
variant	O
of	O
the	O
choice	O
procedure	O
was	O
used	O
because	O
the	O
PROG	O
schedule	O
requires	O
that	O
the	O
animal	B-OG
repeatedly	O
make	O
within	O
-	O
session	O
choices	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
under	O
conditions	O
in	O
which	O
the	O
ratio	O
requirement	O
was	O
gradually	O
incrementing	O
.	O

Moreover	O
,	O
preliminary	O
data	O
indicated	O
that	O
the	O
PROG	O
/	O
chow	O
feeding	O
choice	O
procedure	O
generates	O
much	O
more	O
variability	O
in	O
behavior	O
between	O
animals	B-OG
than	O
the	O
FR5	O
choice	O
procedure	O
,	O
which	O
could	O
be	O
particularly	O
useful	O
for	O
studying	O
neurochemical	O
correlates	O
of	O
individual	O
differences	O
in	O
behavior	O
.	O

To	O
assess	O
the	O
effects	O
of	O
DA	O
antagonism	O
and	O
compare	O
these	O
actions	O
with	O
other	O
conditions	O
,	O
experiments	O
were	O
conducted	O
to	O
determine	O
the	O
effects	O
of	O
the	O
DA	O
D2	B-GP
antagonist	O
haloperidol	O
,	O
the	O
adenosine	B-GP
A2A	I-GP
antagonist	O
MSX	O
-	O
3	O
,	O
the	O
cannabinoid	O
CB1	B-GP
antagonist	O
/	O
inverse	O
agonist	O
and	O
putative	O
appetite	O
suppressant	O
AM251	O
,	O
and	O
the	O
reinforcer	O
devaluation	O
provided	O
by	O
pre	O
-	O
feeding	O
.	O

Furthermore	O
,	O
to	O
investigate	O
signal	O
transduction	O
activity	O
that	O
is	O
potentially	O
related	O
to	O
task	O
performance	O
,	O
expression	O
of	O
DARPP	B-GP
-	I-GP
32	I-GP
that	O
is	O
phosphorylated	O
at	O
the	O
threonine	O
34	O
residue	O
(	O
pDARPP	O
-	O
32	O
-(	O
Thr34	O
)	O
[	O
44	O
]	O
was	O
measured	O
immunohistochemically	O
in	O
4	O
specific	O
regions	O
of	O
interest	O
.	O

pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
immunoreactivity	O
was	O
used	O
to	O
provide	O
a	O
marker	O
of	O
DA	O
-	O
related	O
signal	O
transduction	O
activity	O
,	O
because	O
evidence	O
indicates	O
that	O
DA	O
acting	O
through	O
the	O
D1	B-GP
receptor	I-GP
and	O
the	O
G	B-GP
proteins	I-GP
Gs	B-GP
/	O
Golf	B-GP
activates	O
adenylate	B-GP
cyclase	I-GP
activity	O
,	O
thereby	O
stimulating	O
PKA	B-GP
-	O
mediated	O
phosphorylation	O
of	O
DARPP	B-GP
-	I-GP
32	I-GP
at	O
the	O
Thr34	O
site	O
[	O
45	O
],	O
[	O
46	O
],	O
[	O
47	O
],	O
[	O
48	O
].	O

This	O
experiment	O
was	O
conducted	O
to	O
determine	O
if	O
levels	O
of	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
were	O
higher	O
in	O
animals	B-OG
with	O
high	O
lever	O
pressing	O
output	O
.	O

Nucleus	O
accumbens	O
is	O
implicated	O
in	O
effort	O
-	O
related	O
processes	O
,	O
so	O
both	O
the	O
core	O
and	O
shell	O
divisions	O
were	O
analyzed	O
for	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
activity	O
following	O
a	O
PROG	O
/	O
Choice	O
behavioral	O
session	O
.	O

Because	O
Schweimer	O
and	O
Hauber	O
[	O
43	O
]	O
demonstrated	O
the	O
importance	O
of	O
DA	O
signaling	O
in	O
the	O
anterior	O
cingulate	O
cortex	O
in	O
effort	O
-	O
related	O
decision	O
making	O
,	O
CG1	O
and	O
CG2	O
divisions	O
of	O
the	O
cingulate	O
cortex	O
also	O
were	O
analyzed	O
.	O

It	O
was	O
hypothesized	O
that	O
haloperidol	O
would	O
affect	O
PROG	O
responding	O
in	O
a	O
manner	O
that	O
was	O
not	O
dependent	O
upon	O
decreases	O
in	O
primary	O
food	O
motivation	O
or	O
appetite	O
,	O
and	O
thus	O
would	O
decrease	O
PROG	O
lever	O
pressing	O
but	O
leave	O
chow	O
intake	O
intact	O
.	O

Moreover	O
,	O
it	O
was	O
hypothesized	O
that	O
MSX	O
-	O
3	O
would	O
produce	O
behavioral	O
effects	O
that	O
would	O
be	O
opposite	O
to	O
those	O
produced	O
by	O
haloperidol	O
.	O

Due	O
to	O
the	O
putative	O
appetite	O
suppressant	O
effects	O
of	O
interfering	O
with	O
cannabinoid	O
CB1	B-GP
receptor	I-GP
transmission	O
[	O
1	O
],	O
[	O
30	O
],	O
[	O
49	O
],	O
[	O
50	O
],	O
it	O
was	O
expected	O
that	O
AM251	O
,	O
as	O
well	O
as	O
pre	O
-	O
feeding	O
,	O
would	O
decrease	O
both	O
lever	O
pressing	O
and	O
chow	O
consumption	O
.	O

Finally	O
,	O
it	O
was	O
hypothesized	O
that	O
accumbens	O
DARPP	B-GP
-	I-GP
32	I-GP
immunoreactivity	O
would	O
be	O
greater	O
in	O
animals	B-OG
with	O
high	O
baseline	O
levels	O
of	O
lever	O
pressing	O
(	O
i	O
.	O
e	O
.,	O
“	O
high	O
responders	O
”)	O
than	O
in	O
rats	B-OG
with	O
low	O
levels	O
of	O
lever	O
pressing	O
.	O

Materials	O
and	O
Methods	O

Animals	B-OG

48	O
adult	O
male	O
Sprague	B-OG
-	I-OG
Dawley	I-OG
rats	I-OG
(	O
Harlan	O
,	O
Indianapolis	O
,	O
IN	O
,	O
USA	O
)	O
were	O
housed	O
in	O
a	O
colony	O
at	O
23	O
°	O
C	O
with	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycles	O
(	O
lights	O
on	O
at	O
0	O
∶	O
700	O
h	O
).	O

Rats	B-OG
weighed	O
300	O
–	O
350	O
g	O
at	O
the	O
beginning	O
of	O
the	O
study	O
,	O
and	O
were	O
initially	O
food	O
deprived	O
to	O
85	O
%	O
of	O
their	O
free	O
-	O
feeding	O
body	O
weight	O
for	O
training	O
.	O

Rats	B-OG
were	O
fed	O
supplemental	O
chow	O
to	O
maintain	O
weight	O
throughout	O
the	O
study	O
,	O
with	O
water	O
available	O
ad	O
libitum	O
in	O
the	O
home	O
cages	O
.	O

Despite	O
food	O
restriction	O
,	O
rats	B-OG
were	O
allowed	O
modest	O
weight	O
gain	O
throughout	O
the	O
experiment	O
.	O

All	O
animal	B-OG
protocols	O
were	O
approved	O
by	O
the	O
University	O
of	O
Connecticut	O
Institutional	O
Animal	B-OG
Care	O
and	O
Use	O
Committee	O
,	O
and	O
followed	O
NIH	O
guidelines	O
.	O

Pharmacological	O
Agents	O
and	O
Dose	O
Selection	O

Haloperidol	O
was	O
obtained	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
and	O
was	O
dissolved	O
in	O
0	O
.	O
2	O
%	O
tartaric	O
acid	O
solution	O
.	O

MSX	O
-	O
3	O
((	O
E	O
)-	O
phosphoric	O
acid	O
mono	O
-[	O
3	O
-[	O
8	O
-[	O
2	O
-(	O
3	O
-	O
methoxyphenyl	O
)	O
vinyl	O
]-	O
7	O
-	O
methyl	O
-	O
2	O
,	O
6	O
-	O
dioxo	O
-	O
1	O
-	O
prop	O
-	O
2	O
-	O
ynyl	O
-	O
1	O
,	O
2	O
,	O
6	O
,	O
7	O
-	O
tetrahydropurin	O
-	O
3	O
-	O
yl	O
]	O
propyl	O
]	O
ester	O
disodium	O
salt	O
)	O
was	O
synthesized	O
in	O
the	O
laboratory	O
of	O
Christa	O
Müller	O
(	O
University	O
of	O
Bonn	O
,	O
Bonn	O
,	O
Germany	O
).	O

MSX	O
-	O
3	O
was	O
dissolved	O
in	O
0	O
.	O
9	O
%	O
saline	O
and	O
pH	O
adjusted	O
with	O
1	O
.	O
0	O
M	O
NaOH	O
to	O
a	O
final	O
pH	O
of	O
7	O
.	O
4	O
.	O

AM251	O
was	O
synthesized	O
in	O
the	O
laboratory	O
of	O
Alex	O
Makriyannis	O
(	O
Center	O
for	O
Drug	O
Discovery	O
,	O
Northeastern	O
University	O
,	O
Boston	O
,	O
MA	O
).	O

AM251	O
was	O
dissolved	O
in	O
dimethylsulfoxide	O
(	O
DMSO	O
),	O
Tween	O
80	O
,	O
and	O
0	O
.	O
9	O
%	O
saline	O
at	O
a	O
ratio	O
of	O
1	O
∶	O
1	O
∶	O
8	O
.	O

Doses	O
were	O
selected	O
based	O
on	O
previous	O
work	O
[	O
30	O
],	O
[	O
40	O
],	O
[	O
41	O
].	O

Behavioral	O
Procedures	O

Preliminary	O
studies	O
were	O
conducted	O
to	O
determine	O
the	O
optimal	O
rate	O
at	O
which	O
the	O
schedule	O
progressed	O
(	O
i	O
.	O
e	O
.,	O
number	O
of	O
reinforcements	O
per	O
ratio	O
level	O
and	O
by	O
how	O
much	O
the	O
ratio	O
requirement	O
increased	O
with	O
each	O
level	O
).	O

It	O
was	O
found	O
that	O
by	O
having	O
to	O
complete	O
15	O
ratios	O
at	O
each	O
ratio	O
level	O
,	O
rats	B-OG
generally	O
lever	O
pressed	O
at	O
higher	O
levels	O
before	O
switching	O
to	O
chow	O
.	O

Behavioral	O
sessions	O
were	O
conducted	O
in	O
operant	O
conditioning	O
chambers	O
(	O
28	O
×	O
23	O
×	O
23	O
cm3	O
;	O
Med	O
Associates	O
).	O

Rats	B-OG
were	O
initially	O
trained	O
to	O
lever	O
press	O
on	O
a	O
continuous	O
reinforcement	O
schedule	O
(	O
30	O
-	O
min	O
sessions	O
;	O
45	O
-	O
mg	O
high	O
carbohydrate	O
pellets	O
,	O
Bio	O
-	O
serv	O
,	O
Frenchtown	O
,	O
NJ	O
,	O
USA	O
)	O
for	O
1	O
week	O
,	O
and	O
then	O
were	O
shifted	O
to	O
the	O
PROG	O
schedule	O
(	O
30	O
-	O
min	O
sessions	O
,	O
5	O
days	O
/	O
week	O
)	O
for	O
several	O
additional	O
weeks	O
.	O

For	O
PROG	O
sessions	O
,	O
the	O
ratio	O
started	O
at	O
FR1	O
and	O
was	O
increased	O
by	O
one	O
additional	O
response	O
every	O
time	O
15	O
reinforcements	O
were	O
obtained	O
(	O
FR1	O
×	O
15	O
,	O
FR2	O
×	O
15	O
,	O
FR3	O
×	O
15	O
,…).	O

Additionally	O
,	O
this	O
schedule	O
included	O
a	O
“	O
time	O
-	O
out	O
”	O
feature	O
that	O
deactivated	O
the	O
response	O
lever	O
if	O
2	O
minutes	O
elapsed	O
without	O
a	O
ratio	O
being	O
completed	O
.	O

Upon	O
reaching	O
stable	O
baseline	O
responding	O
,	O
chow	O
was	O
then	O
introduced	O
.	O

Weighed	O
amounts	O
of	O
laboratory	O
chow	O
(	O
Laboratory	O
Diet	O
,	O
5P00	O
Prolab	O
RMH	O
3000	O
,	O
Purina	O
Mills	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
;	O
typically	O
15	O
–	O
20	O
g	O
)	O
were	O
concurrently	O
available	O
on	O
the	O
floor	O
of	O
the	O
chamber	O
during	O
the	O
PROG	O
sessions	O
.	O

At	O
the	O
end	O
of	O
the	O
session	O
,	O
rats	B-OG
were	O
removed	O
from	O
the	O
chamber	O
,	O
and	O
food	O
intake	O
was	O
determined	O
by	O
weighing	O
the	O
remaining	O
food	O
(	O
including	O
spillage	O
).	O

Rats	B-OG
were	O
trained	O
until	O
they	O
attained	O
stable	O
levels	O
of	O
baseline	O
lever	O
pressing	O
and	O
chow	O
intake	O
,	O
after	O
which	O
drug	O
testing	O
began	O
.	O

For	O
most	O
baseline	O
days	O
rats	B-OG
did	O
not	O
receive	O
supplemental	O
feeding	O
,	O
however	O
,	O
over	O
weekends	O
and	O
after	O
drug	O
tests	O
,	O
rats	B-OG
received	O
supplemental	O
chow	O
in	O
the	O
home	O
cage	O
.	O

On	O
baseline	O
and	O
drug	O
treatment	O
days	O
,	O
rats	B-OG
normally	O
consumed	O
all	O
the	O
operant	O
pellets	O
that	O
were	O
delivered	O
during	O
each	O
session	O
.	O

Experimental	O
Procedures	O

For	O
experiments	O
1	O
–	O
3a	O
and	O
4	O
,	O
the	O
same	O
group	O
of	O
animals	B-OG
was	O
used	O
(	O
n	O
=	O
32	O
),	O
while	O
a	O
different	O
group	O
of	O
animals	B-OG
was	O
used	O
for	O
experiment	O
3b	O
(	O
n	O
=	O
16	O
).	O

For	O
all	O
experiments	O
using	O
drug	O
manipulations	O
(	O
1	O
,	O
2	O
,	O
3b	O
),	O
all	O
animals	B-OG
were	O
given	O
a	O
single	O
vehicle	O
injection	O
1	O
week	O
prior	O
to	O
the	O
beginning	O
of	O
testing	O
to	O
habituate	O
them	O
to	O
being	O
injected	O
.	O

Experiments	O
1	O
,	O
2	O
,	O
and	O
3b	O
used	O
a	O
within	O
-	O
group	O
design	O
in	O
which	O
each	O
rat	B-OG
received	O
all	O
drug	O
or	O
vehicle	O
treatments	O
(	O
IP	O
)	O
in	O
their	O
particular	O
experiment	O
in	O
a	O
randomly	O
varied	O
order	O
(	O
one	O
treatment	O
per	O
week	O
).	O

Baseline	O
training	O
sessions	O
(	O
i	O
.	O
e	O
.,	O
non	O
-	O
drug	O
)	O
were	O
conducted	O
4	O
days	O
per	O
week	O
.	O

Experiment	O
1	O
:	O
Effects	O
of	O
the	O
dopamine	O
D2	B-GP
antagonist	O
haloperidol	O
on	O
PROG	O
/	O
chow	O
feeding	O
choice	O
performance	O

To	O
assess	O
the	O
effects	O
of	O
haloperidol	O
,	O
rats	B-OG
were	O
trained	O
on	O
the	O
PROG	O
/	O
chow	O
procedure	O
described	O
above	O
.	O

On	O
test	O
days	O
,	O
animals	B-OG
received	O
injections	O
of	O
0	O
.	O
025	O
,	O
0	O
.	O
05	O
,	O
0	O
.	O
1	O
mg	O
/	O
kg	O
haloperidol	O
or	O
vehicle	O
,	O
50	O
minutes	O
prior	O
to	O
behavioral	O
testing	O
.	O

Experiment	O
2	O
:	O
Effects	O
of	O
the	O
adenosine	B-GP
A2A	I-GP
antagonist	O
MSX	O
-	O
3	O
on	O
PROG	O
/	O
chow	O
feeding	O
choice	O
performance	O

To	O
assess	O
the	O
effects	O
of	O
the	O
adenosine	B-GP
A2A	I-GP
antagonist	O
MSX	O
-	O
3	O
,	O
the	O
same	O
group	O
of	O
animals	B-OG
was	O
used	O
.	O

The	O
animals	B-OG
were	O
first	O
given	O
1	O
week	O
off	O
from	O
any	O
drug	O
testing	O
,	O
but	O
continued	O
normal	O
baseline	O
training	O
.	O

On	O
test	O
days	O
,	O
animals	B-OG
received	O
injections	O
of	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
2	O
.	O
0	O
mg	O
/	O
kg	O
MSX	O
-	O
3	O
or	O
vehicle	O
,	O
20	O
minutes	O
prior	O
to	O
behavioral	O
testing	O
.	O

Experiment	O
3a	O
/	O
b	O
:	O
Effects	O
of	O
appetite	O
manipulations	O
on	O
PROG	O
/	O
chow	O
performance	O

3a	O
.	O

Effects	O
of	O
pre	O
-	O
feeding	O
to	O
reduce	O
food	O
motivation	O
.	O
To	O
assess	O
the	O
effects	O
of	O
pre	O
-	O
feeding	O
,	O
the	O
same	O
group	O
of	O
animals	B-OG
was	O
again	O
given	O
1	O
week	O
of	O
additional	O
baseline	O
training	O
after	O
experiment	O
2	O
.	O

The	O
night	O
before	O
testing	O
,	O
animals	B-OG
were	O
taken	O
off	O
of	O
food	O
restriction	O
and	O
given	O
ad	O
libitum	O
access	O
to	O
lab	O
chow	O
.	O

On	O
the	O
test	O
day	O
,	O
several	O
hours	O
before	O
behavioral	O
testing	O
,	O
animals	B-OG
were	O
given	O
ad	O
libitum	O
access	O
to	O
Bio	O
-	O
serv	O
pellets	O
in	O
the	O
home	O
cage	O
.	O

Performance	O
on	O
the	O
test	O
day	O
was	O
then	O
compared	O
to	O
performance	O
on	O
the	O
previous	O
baseline	O
day	O
.	O

3b	O
:	O
Effects	O
of	O
the	O
cannabinoid	O
CB1	B-GP
inverse	O
agonist	O
and	O
putative	O
appetite	O
suppressant	O
AM251	O
.	O
For	O
assessment	O
of	O
the	O
effect	O
of	O
AM251	O
,	O
a	O
new	O
group	O
of	O
animals	B-OG
(	O
n	O
=	O
16	O
)	O
were	O
trained	O
on	O
the	O
PROG	O
/	O
chow	O
feeding	O
choice	O
procedure	O
described	O
above	O
.	O

On	O
test	O
days	O
,	O
animals	B-OG
received	O
injections	O
of	O
2	O
.	O
0	O
,	O
4	O
.	O
0	O
,	O
8	O
.	O
0	O
mg	O
/	O
kg	O
AM251	O
or	O
vehicle	O
,	O
30	O
minutes	O
prior	O
to	O
testing	O
,	O
once	O
per	O
week	O
,	O
in	O
a	O
randomly	O
varied	O
order	O
.	O

Experiment	O
4	O
:	O
Effects	O
of	O
PROG	O
/	O
chow	O
responding	O
on	O
pDARPP32	O
-	O
THR34	O
expression	O
:	O
high	O
vs	O
.	O
low	O
responders	O

Following	O
the	O
conclusion	O
of	O
experiment	O
3	O
,	O
animals	B-OG
(	O
n	O
=	O
32	O
)	O
were	O
given	O
1	O
week	O
to	O
re	O
-	O
stabilize	O
their	O
baselines	O
.	O

During	O
the	O
following	O
week	O
,	O
90	O
minutes	O
after	O
a	O
baseline	O
training	O
session	O
,	O
animals	B-OG
were	O
sacrificed	O
and	O
perfused	O
to	O
obtain	O
tissue	O
for	O
pDARPP32	O
-(	O
Thr34	O
)	O
immunohistochemical	O
analysis	O
.	O

For	O
statistical	O
analysis	O
,	O
these	O
animals	B-OG
were	O
divided	O
into	O
two	O
groups	O
(	O
high	O
performers	O
and	O
low	O
performers	O
,	O
determined	O
by	O
a	O
median	O
split	O
of	O
lever	O
pressing	O
on	O
the	O
day	O
of	O
perfusion	O
).	O

pDARPP32	O
(	O
Thr34	O
)	O
visualization	O
and	O
quantification	O

Free	O
floating	O
coronal	O
sections	O
(	O
50	O
µm	O
)	O
were	O
serially	O
cut	O
using	O
a	O
cryostat	O
(	O
Weymouth	O
,	O
MA	O
,	O
USA	O
)	O
and	O
rinsed	O
in	O
0	O
.	O
01	O
M	O
PBS	O
(	O
pH	O
7	O
.	O
4	O
).	O

pDARPP32	O
-(	O
Thr34	O
)	O
immunohistochemistry	O
was	O
conducted	O
according	O
to	O
the	O
methods	O
described	O
previously	O
by	O
Segovia	O
et	O
al	O
.	O
(	O
2012	O
).	O

The	O
primary	O
anti	O
-	O
pDARPP32	O
-(	O
Thr34	O
)	O
antibody	O
was	O
used	O
at	O
a	O
concentration	O
of	O
1	O
∶	O
1000	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
USA	O
)	O
for	O
48	O
h	O
incubation	O
,	O
and	O
the	O
secondary	O
antibody	O
was	O
anti	O
-	O
rabbit	B-OG
HRP	B-GP
conjugate	O
,	O
envision	O
plus	O
(	O
DAKO	O
,	O
Carpinteria	O
,	O
CA	O
,	O
USA	O
).	O

The	O
immunohistochemical	O
reaction	O
was	O
developed	O
using	O
diaminobenzidine	O
(	O
DAB	O
)	O
as	O
the	O
chromagen	O
.	O

The	O
mounted	O
and	O
cover	O
-	O
slipped	O
sections	O
were	O
examined	O
and	O
photographed	O
using	O
a	O
Nikon	O
Eclipse	O
E600	O
(	O
Melville	O
,	O
NY	O
,	O
USA	O
)	O
microscope	O
equipped	O
with	O
an	O
Insight	O
Spot	O
digital	O
camera	O
(	O
Diagnostic	O
Instruments	O
,	O
Inc	O
).	O

Images	O
of	O
the	O
regions	O
of	O
interest	O
were	O
magnified	O
at	O
20	O
×	O
and	O
captured	O
digitally	O
using	O
SPOT	O
software	O
.	O

Cells	O
that	O
were	O
positively	O
labeled	O
for	O
pDARPP32	O
-(	O
Thr	O
34	O
)	O
were	O
quantified	O
with	O
ImageJ	O
software	O
(	O
v	O
.	O

1	O
.	O
42	O
,	O
National	O
Institutes	O
of	O
Health	O
sponsored	O
image	O
analysis	O
program	O
)	O
and	O
a	O
macro	O
written	O
to	O
automate	O
particle	O
counting	O
within	O
regions	O
of	O
interest	O
(	O
1000	O
×	O
1000	O
µm	O
).	O

For	O
each	O
animal	B-OG
,	O
cell	O
counts	O
were	O
obtained	O
bilaterally	O
from	O
at	O
least	O
three	O
sections	O
,	O
and	O
counts	O
were	O
averaged	O
across	O
sides	O
and	O
sections	O
.	O

All	O
cell	O
counting	O
was	O
done	O
by	O
someone	O
who	O
was	O
blind	O
to	O
the	O
experimental	O
conditions	O
.	O

Statistical	O
Analysis	O

For	O
the	O
behavioral	O
pharmacology	O
experiments	O
,	O
number	O
of	O
lever	O
presses	O
,	O
maximum	O
ratio	O
achieved	O
,	O
active	O
lever	O
time	O
(	O
in	O
seconds	O
)	O
and	O
chow	O
intake	O
(	O
grams	O
)	O
were	O
analyzed	O
using	O
repeated	O
measures	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
).	O

Non	O
-	O
orthogonal	O
planned	O
comparisons	O
using	O
the	O
ANOVA	O
error	O
term	O
[	O
51	O
]	O
were	O
used	O
to	O
compare	O
each	O
treatment	O
with	O
the	O
vehicle	O
control	O
.	O

In	O
addition	O
,	O
to	O
provide	O
another	O
statistical	O
measure	O
of	O
the	O
reciprocal	O
relationship	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
in	O
each	O
experiment	O
,	O
correlations	O
were	O
performed	O
between	O
number	O
of	O
lever	O
presses	O
and	O
chow	O
intake	O
data	O
collapsed	O
across	O
all	O
conditions	O
within	O
the	O
experiment	O
.	O

This	O
measure	O
has	O
been	O
used	O
in	O
previous	O
studies	O
[	O
25	O
],	O
[	O
27	O
],	O
and	O
is	O
potentially	O
influenced	O
by	O
both	O
between	O
subject	O
and	O
treatment	O
-	O
related	O
variability	O
in	O
lever	O
pressing	O
and	O
chow	O
intake	O
.	O

Thus	O
,	O
in	O
order	O
to	O
control	O
for	O
the	O
effect	O
of	O
between	O
-	O
subject	O
variability	O
on	O
this	O
measure	O
,	O
partial	O
correlations	O
that	O
controlled	O
for	O
the	O
vehicle	O
level	O
of	O
lever	O
pressing	O
also	O
were	O
performed	O
.	O

For	O
experiment	O
4	O
,	O
pDARPP32	O
-(	O
Thr34	O
)	O
cell	O
counts	O
were	O
analyzed	O
for	O
differences	O
in	O
expression	O
between	O
high	O
and	O
low	O
responders	O
(	O
after	O
a	O
median	O
split	O
of	O
the	O
lever	O
pressing	O
data	O
)	O
for	O
each	O
of	O
4	O
regions	O
of	O
interest	O
,	O
and	O
t	O
-	O
tests	O
were	O
performed	O
to	O
determine	O
significant	O
differences	O
.	O

Results	O

Experiment	O
1	O
:	O
Effects	O
of	O
the	O
DA	O
D2	B-GP
antagonist	O
haloperidol	O

Haloperidol	O
significantly	O
decreased	O
the	O
number	O
of	O
lever	O
presses	O
(	O
F	O
(	O
3	O
,	O
93	O
)	O
=	O
4	O
.	O
598	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
see	O
figure	O
1A	O
).	O

Planned	O
comparisons	O
revealed	O
that	O
there	O
was	O
a	O
significant	O
difference	O
between	O
0	O
.	O
1	O
mg	O
/	O
kg	O
haloperidol	O
and	O
vehicle	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Haloperidol	O
also	O
significantly	O
decreased	O
maximum	O
ratio	O
achieved	O
(	O
F	O
(	O
3	O
,	O
93	O
)	O
=	O
8	O
.	O
661	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
figure	O
1B	O
),	O
and	O
the	O
amount	O
of	O
time	O
the	O
lever	O
remained	O
active	O
(	O
F	O
(	O
3	O
,	O
93	O
)	O
=	O
6	O
.	O
723	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
figure	O
1C	O
);	O
for	O
both	O
measures	O
,	O
planned	O
comparisons	O
showed	O
a	O
significant	O
difference	O
between	O
vehicle	O
and	O
0	O
.	O
1	O
mg	O
/	O
kg	O
haloperidol	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Haloperidol	O
produced	O
no	O
significant	O
effects	O
on	O
chow	O
consumption	O
in	O
the	O
dose	O
range	O
tested	O
(	O
figure	O
1D	O
).	O

However	O
,	O
there	O
was	O
a	O
tendency	O
for	O
animals	B-OG
that	O
had	O
high	O
vehicle	O
rates	O
of	O
responding	O
,	O
and	O
correspondingly	O
low	O
vehicle	O
levels	O
of	O
chow	O
intake	O
,	O
to	O
show	O
increases	O
in	O
chow	O
intake	O
with	O
haloperidol	O
;	O
this	O
was	O
marked	O
by	O
a	O
significant	O
correlation	O
between	O
vehicle	O
number	O
of	O
lever	O
presses	O
and	O
the	O
difference	O
in	O
chow	O
consumption	O
between	O
vehicle	O
and	O
the	O
highest	O
dose	O
of	O
haloperidol	O
(	O
r	O
=	O
0	O
.	O
69	O
,	O
df	O
=	O
30	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

Collapsed	O
across	O
all	O
conditions	O
,	O
there	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
number	O
of	O
lever	O
presses	O
and	O
chow	O
consumption	O
(	O
r	O
=	O
−	O
0	O
.	O
765	O
,	O
df	O
=	O
126	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
which	O
demonstrated	O
the	O
overall	O
inverse	O
relationship	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
.	O

Moreover	O
,	O
the	O
partial	O
correlation	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
that	O
controlled	O
for	O
between	O
-	O
subject	O
variability	O
also	O
was	O
statistically	O
significant	O
(−	O
0	O
.	O
557	O
,	O
df	O
=	O
125	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
indicating	O
that	O
the	O
inverse	O
relation	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
was	O
evident	O
across	O
treatments	O
even	O
if	O
one	O
controlled	O
for	O
the	O
between	O
-	O
subject	O
variability	O
in	O
lever	O
pressing	O
.	O

Effects	O
of	O
the	O
dopamine	O
D2	B-GP
antagonist	O
haloperidol	O
on	O
PROG	O
/	O
chow	O
performance	O
.	O

On	O
measures	O
of	O
lever	O
pressing	O
,	O
mean	O
(±	O
SEM	O
)	O
total	O
lever	O
presses	O
(	O
A	O
),	O
maximum	O
ratio	O
achieved	O
(	O
B	O
),	O
and	O
active	O
lever	O
time	O
(	O
measured	O
in	O
seconds	O
,	O
C	O
),	O
haloperidol	O
significantly	O
decreased	O
at	O
the	O
highest	O
dose	O
of	O
0	O
.	O
1	O
mg	O
/	O
kg	O
.	O

Chow	O
consumption	O
(	O
mean	O
±	O
SEM	O
,	O
in	O
grams	O
)	O
during	O
test	O
sessions	O
was	O
unaffected	O
by	O
any	O
dose	O
tested	O
(	O
D	O
).	O

(*	O
p	O
<	O
0	O
.	O
05	O
,	O
different	O
from	O
vehicle	O
)	O

Experiment	O
2	O
:	O
Effects	O
of	O
the	O
adenosine	B-GP
A2A	I-GP
antagonist	O
MSX	O
-	O
3	O

MSX	O
-	O
3	O
significantly	O
increased	O
number	O
of	O
lever	O
presses	O
(	O
F	O
(	O
3	O
,	O
93	O
)	O
=	O
4	O
.	O
120	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
figure	O
2A	O
),	O
and	O
planned	O
comparisons	O
showed	O
that	O
both	O
1	O
.	O
0	O
and	O
2	O
.	O
0	O
mg	O
/	O
kg	O
doses	O
of	O
MSX	O
-	O
3	O
increased	O
number	O
of	O
lever	O
presses	O
compared	O
to	O
vehicle	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

There	O
also	O
was	O
a	O
significant	O
increase	O
in	O
maximum	O
ratio	O
achieved	O
(	O
F	O
(	O
3	O
,	O
93	O
)	O
=	O
8	O
.	O
206	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
see	O
figure	O
2B	O
),	O
with	O
the	O
1	O
.	O
0	O
and	O
2	O
.	O
0	O
mg	O
/	O
kg	O
doses	O
of	O
MSX	O
-	O
3	O
differing	O
significantly	O
from	O
vehicle	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Furthermore	O
,	O
MSX	O
-	O
3	O
increased	O
active	O
lever	O
time	O
(	O
F	O
(	O
3	O
,	O
93	O
)	O
=	O
3	O
.	O
784	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
figure	O
2C	O
),	O
with	O
the	O
2	O
.	O
0	O
mg	O
/	O
kg	O
does	O
of	O
MSX	O
-	O
3	O
being	O
significantly	O
affected	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

MSX	O
-	O
3	O
decreased	O
chow	O
intake	O
(	O
F	O
(	O
3	O
,	O
93	O
)	O
=	O
8	O
.	O
017	O
,	O
p	O
<	O
0	O
.	O
01	O
;	O
figure	O
2D	O
),	O
with	O
a	O
significant	O
effect	O
at	O
2	O
.	O
0	O
mg	O
/	O
kg	O
MSX	O
-	O
3	O
compared	O
to	O
vehicle	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

As	O
with	O
experiment	O
1	O
,	O
there	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
lever	O
presses	O
and	O
chow	O
intake	O
when	O
the	O
data	O
were	O
collapsed	O
across	O
all	O
conditions	O
(	O
r	O
=	O
−	O
0	O
.	O
781	O
,	O
df	O
=	O
126	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

In	O
addition	O
,	O
the	O
partial	O
correlation	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
that	O
controlled	O
for	O
between	O
-	O
subject	O
variability	O
also	O
was	O
statistically	O
significant	O
(−	O
0	O
.	O
597	O
,	O
df	O
=	O
125	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

Thus	O
,	O
as	O
with	O
the	O
haloperidol	O
experiment	O
,	O
the	O
inverse	O
relation	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
was	O
evident	O
across	O
drug	O
treatments	O
even	O
if	O
one	O
controlled	O
for	O
the	O
between	O
-	O
subject	O
variability	O
in	O
lever	O
pressing	O
.	O

Effects	O
of	O
the	O
adenosine	B-GP
A2A	I-GP
antagonist	O
MSX	O
-	O
3	O
on	O
PROG	O
/	O
chow	O
performance	O
.	O

On	O
measures	O
of	O
lever	O
pressing	O
,	O
mean	O
(±	O
SEM	O
)	O
total	O
lever	O
presses	O
(	O
A	O
)	O
and	O
maximum	O
ratio	O
achieved	O
(	O
B	O
)	O
were	O
both	O
significantly	O
increased	O
at	O
doses	O
of	O
1	O
.	O
0	O
and	O
2	O
.	O
0	O
mg	O
/	O
kg	O
while	O
active	O
lever	O
time	O
(	O
measured	O
in	O
seconds	O
,	O
C	O
)	O
was	O
only	O
increased	O
at	O
a	O
dose	O
of	O
2	O
.	O
0	O
mg	O
/	O
kg	O
.	O

Chow	O
consumption	O
(	O
mean	O
±	O
SEM	O
,	O
in	O
grams	O
)	O
during	O
test	O
sessions	O
was	O
significantly	O
decreased	O
at	O
the	O
dose	O
of	O
2	O
.	O
0	O
mg	O
/	O
kg	O
(	O
D	O
).	O

(*	O
p	O
<	O
0	O
.	O
05	O
,	O
different	O
from	O
vehicle	O
)	O

Experiment	O
3	O
:	O
Effects	O
of	O
appetite	O
-	O
related	O
manipulations	O
on	O
PROG	O
/	O
chow	O
performance	O
:	O
effects	O
of	O
pre	O
-	O
feeding	O
and	O
the	O
putative	O
appetite	O
suppressant	O
AM251	O

Experiment	O
3a	O
studied	O
the	O
effects	O
of	O
pre	O
-	O
feeding	O
on	O
PROG	O
/	O
chow	O
intake	O
choice	O
performance	O
(	O
figures	O
3A	O
–	O
D	O
).	O

Compared	O
to	O
the	O
previous	O
baseline	O
day	O
,	O
pre	O
-	O
feeding	O
the	O
animals	B-OG
prior	O
to	O
the	O
session	O
produced	O
marked	O
decreases	O
in	O
number	O
of	O
lever	O
presses	O
(	O
t	O
=	O
2	O
.	O
96	O
,	O
df	O
=	O
31	O
,	O
p	O
<	O
0	O
.	O
05	O
),	O
and	O
maximum	O
ratio	O
achieved	O
(	O
t	O
=	O
3	O
.	O
94	O
,	O
df	O
=	O
31	O
,	O
p	O
<	O
0	O
.	O
05	O
),	O
but	O
no	O
significant	O
effect	O
on	O
active	O
lever	O
time	O
.	O

Pre	O
-	O
feeding	O
significantly	O
decreased	O
chow	O
intake	O
(	O
t	O
=	O
13	O
.	O
69	O
,	O
df	O
=	O
31	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
compared	O
to	O
previous	O
day	O
baseline	O
performance	O
.	O

There	O
was	O
no	O
significant	O
overall	O
correlation	O
between	O
number	O
of	O
lever	O
presses	O
and	O
chow	O
consumption	O
(	O
r	O
=	O
0	O
.	O
12	O
,	O
df	O
=	O
62	O
,	O
n	O
.	O
s	O
.),	O
and	O
no	O
significant	O
partial	O
correlation	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
when	O
we	O
controlled	O
for	O
the	O
between	O
-	O
subject	O
variability	O
in	O
lever	O
pressing	O
(	O
r	O
=	O
0	O
.	O
156	O
,	O
df	O
=	O
61	O
,	O
n	O
.	O
s	O
.).	O

Experiment	O
3b	O
studied	O
the	O
effects	O
of	O
the	O
cannabinoid	O
CB1	B-GP
inverse	O
agonist	O
AM251	O
.	O

AM251	O
decreased	O
the	O
number	O
of	O
lever	O
presses	O
(	O
F	O
(	O
3	O
,	O
45	O
)	O
=	O
3	O
.	O
891	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
figure	O
4A	O
),	O
and	O
the	O
maximum	O
ratio	O
achieved	O
(	O
F	O
(	O
3	O
,	O
45	O
)	O
=	O
5	O
.	O
811	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
see	O
figure	O
4B	O
).	O

Planned	O
comparisons	O
showed	O
that	O
with	O
both	O
measures	O
,	O
only	O
the	O
highest	O
dose	O
of	O
8	O
.	O
0	O
mg	O
/	O
kg	O
AM251	O
significantly	O
differed	O
from	O
vehicle	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

AM251	O
did	O
not	O
produce	O
any	O
significant	O
changes	O
in	O
active	O
lever	O
time	O
(	O
figure	O
4C	O
),	O
but	O
it	O
significantly	O
decrease	O
chow	O
intake	O
(	O
F	O
(	O
3	O
,	O
45	O
)	O
=	O
45	O
.	O
634	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
figure	O
4D	O
),	O
with	O
all	O
doses	O
differing	O
from	O
vehicle	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

There	O
was	O
no	O
significant	O
overall	O
correlation	O
between	O
number	O
of	O
lever	O
presses	O
and	O
chow	O
consumption	O
(	O
r	O
=	O
−	O
0	O
.	O
05	O
,	O
df	O
=	O
62	O
,	O
n	O
.	O
s	O
.),	O
and	O
no	O
significant	O
partial	O
correlation	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
when	O
we	O
controlled	O
for	O
the	O
between	O
-	O
subject	O
variability	O
in	O
lever	O
pressing	O
(	O
r	O
=	O
0	O
.	O
234	O
,	O
df	O
=	O
61	O
,	O
n	O
.	O
s	O
.).	O

Effects	O
of	O
prefeeding	O
on	O
PROG	O
/	O
chow	O
performance	O
.	O

On	O
measures	O
of	O
lever	O
pressing	O
,	O
mean	O
(+	O
SEM	O
)	O
total	O
lever	O
presses	O
(	O
A	O
),	O
maximum	O
ratio	O
achieved	O
(	O
B	O
),	O
and	O
active	O
lever	O
time	O
(	O
measured	O
in	O
seconds	O
,	O
C	O
)	O
were	O
all	O
significantly	O
decreased	O
with	O
prefeeding	O
.	O

Chow	O
consumption	O
(	O
mean	O
+	O
SEM	O
,	O
in	O
grams	O
)	O
during	O
test	O
sessions	O
was	O
significantly	O
decreased	O
by	O
prefeeding	O
animals	B-OG
prior	O
to	O
the	O
test	O
session	O
(	O
D	O
).	O

(*	O
p	O
<	O
0	O
.	O
05	O
,	O
different	O
from	O
vehicle	O
)	O

Effects	O
of	O
the	O
cannabinoid	O
CB1	B-GP
inverse	O
agonist	O
AM251	O
on	O
PROG	O
/	O
chow	O
performance	O
.	O

On	O
measures	O
of	O
lever	O
pressing	O
,	O
mean	O
(±	O
SEM	O
)	O
total	O
lever	O
presses	O
(	O
A	O
)	O
and	O
maximum	O
ratio	O
achieved	O
(	O
B	O
)	O
were	O
significantly	O
decreased	O
at	O
8	O
.	O
0	O
mg	O
/	O
kg	O
while	O
active	O
lever	O
time	O
(	O
measured	O
in	O
seconds	O
,	O
C	O
)	O
was	O
unaffected	O
at	O
any	O
dose	O
tested	O
.	O

Chow	O
consumption	O
(	O
mean	O
±	O
SEM	O
,	O
in	O
grams	O
)	O
during	O
test	O
sessions	O
was	O
significantly	O
decreased	O
at	O
2	O
.	O
0	O
,	O
4	O
.	O
0	O
and	O
8	O
.	O
0	O
mg	O
/	O
kg	O
doses	O
(	O
D	O
).	O

(*	O
p	O
<	O
0	O
.	O
05	O
,	O
different	O
from	O
vehicle	O
)	O

Experiment	O
4	O
:	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
Immunohistochemistry	O
in	O
high	O
and	O
low	O
responders	O

Performance	O
on	O
the	O
PROG	O
/	O
chow	O
feeding	O
choice	O
task	O
was	O
highly	O
variable	O
;	O
some	O
rats	B-OG
lever	O
pressed	O
fewer	O
than	O
100	O
times	O
and	O
had	O
high	O
levels	O
of	O
chow	O
intake	O
,	O
while	O
others	O
lever	O
pressed	O
more	O
than	O
1000	O
times	O
and	O
consumed	O
small	O
amounts	O
of	O
chow	O
.	O

This	O
variability	O
was	O
seen	O
across	O
all	O
the	O
experiments	O
described	O
above	O
,	O
and	O
in	O
some	O
cases	O
was	O
related	O
to	O
the	O
drug	O
effects	O
seen	O
.	O

For	O
example	O
,	O
the	O
effects	O
of	O
haloperidol	O
were	O
more	O
marked	O
in	O
rats	B-OG
with	O
higher	O
control	O
levels	O
of	O
lever	O
pressing	O
.	O

When	O
a	O
median	O
split	O
was	O
done	O
,	O
and	O
high	O
and	O
low	O
lever	O
pressing	O
was	O
used	O
as	O
a	O
factor	O
in	O
a	O
2	O
×	O
4	O
factorial	O
ANOVA	O
,	O
there	O
was	O
an	O
overall	O
effect	O
of	O
dose	O
(	O
F	O
[	O
3	O
,	O
90	O
]	O
=	O
5	O
.	O
071	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
importantly	O
,	O
a	O
dose	O
by	O
group	O
interaction	O
(	O
F	O
[	O
3	O
,	O
90	O
]	O
=	O
4	O
.	O
189	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

Although	O
the	O
repeated	O
measures	O
ANOVA	O
demonstrated	O
that	O
both	O
low	O
and	O
high	O
responders	O
showed	O
significant	O
decreases	O
in	O
number	O
of	O
lever	O
presses	O
(	O
low	O
responders	O
:	O
F	O
(	O
3	O
,	O
45	O
)	O
=	O
2	O
.	O
790	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
high	O
responders	O
:	O
F	O
(	O
3	O
,	O
45	O
)	O
=	O
4	O
.	O
638	O
,	O
p	O
<	O
0	O
.	O
05	O
),	O
analysis	O
of	O
effect	O
sizes	O
showed	O
that	O
the	O
suppressive	O
effect	O
of	O
haloperidol	O
on	O
number	O
of	O
lever	O
presses	O
was	O
greater	O
in	O
high	O
responders	O
(	O
eta2	O
=	O
0	O
.	O
236	O
)	O
than	O
low	O
responders	O
(	O
eta2	O
=	O
0	O
.	O
157	O
).	O

Similar	O
analyses	O
revealed	O
differences	O
between	O
high	O
and	O
low	O
responders	O
in	O
the	O
AM251	O
experiment	O
,	O
with	O
only	O
the	O
high	O
responders	O
showing	O
a	O
significant	O
drug	O
effect	O
on	O
number	O
of	O
lever	O
presses	O
.	O

Because	O
of	O
this	O
large	O
variability	O
,	O
the	O
final	O
experiment	O
investigated	O
potential	O
neurochemical	O
differences	O
between	O
high	O
and	O
low	O
responders	O
,	O
using	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
as	O
a	O
marker	O
of	O
signal	O
transduction	O
activity	O
.	O

To	O
analyze	O
the	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
data	O
,	O
a	O
median	O
split	O
based	O
upon	O
behavioral	O
performance	O
during	O
the	O
final	O
test	O
day	O
was	O
performed	O
,	O
yielding	O
two	O
groups	O
:	O
high	O
responders	O
(	O
n	O
=	O
16	O
,	O
mean	O
=	O
812	O
.	O
44	O
,	O
SEM	O
=	O
201	O
.	O
68	O
,	O
range	O
=	O
205	O
–	O
2852	O
)	O
and	O
low	O
responders	O
(	O
n	O
=	O
16	O
,	O
mean	O
=	O
116	O
.	O
31	O
,	O
SEM	O
=	O
12	O
.	O
81	O
,	O
range	O
=	O
54	O
–	O
190	O
).	O

Four	O
regions	O
of	O
interest	O
were	O
selected	O
for	O
analysis	O
:	O
cingulate	O
cortex	O
CG1	O
/	O
CG2	O
and	O
accumbens	O
core	O
/	O
shell	O
(	O
Figures	O
5	O
–	O
6	O
).	O

There	O
were	O
no	O
differences	O
in	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
between	O
high	O
and	O
low	O
responders	O
in	O
CG1	O
(	O
t	O
=	O
−	O
0	O
.	O
066	O
,	O
df	O
=	O
28	O
,	O
n	O
.	O
s	O
.)	O
or	O
CG2	O
(	O
t	O
=	O
0	O
.	O
172	O
,	O
df	O
=	O
25	O
,	O
n	O
.	O
s	O
.).	O

Nucleus	O
accumbens	O
shell	O
showed	O
no	O
significant	O
differences	O
in	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
between	O
high	O
and	O
low	O
responders	O
(	O
t	O
=	O
1	O
.	O
415	O
,	O
df	O
=	O
30	O
,	O
n	O
.	O
s	O
.),	O
but	O
nucleus	O
accumbens	O
core	O
showed	O
a	O
significant	O
difference	O
in	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
between	O
high	O
and	O
low	O
responders	O
(	O
t	O
=	O
2	O
.	O
703	O
,	O
df	O
=	O
29	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
figures	O
5	O
–	O
6	O
).	O

pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
immunocytochemistry	O
.	O

(	O
A	O
and	O
B	O
)	O
Atlas	O
plates	O
(	O
modified	O
from	O
Paxinos	O
and	O
Watson	O
[	O
68	O
]	O
with	O
regions	O
of	O
interest	O
denoted	O
by	O
squares	O
.	O

(	O
C	O
)	O
High	O
magnification	O
photomicrograph	O
of	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
immunoreactive	O
cells	O
at	O
40	O
×	O
magnification	O
.	O

Several	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
positive	O
cells	O
are	O
shown	O
,	O
including	O
a	O
darkly	O
staining	O
cell	O
,	O
with	O
clear	O
soma	O
and	O
dendritic	O
processes	O
(	O
arrow	O
)	O
(	O
D	O
)	O
Mean	O
(±	O
SEM	O
)	O
number	O
of	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
positive	O
cells	O
counted	O
in	O
each	O
region	O
of	O
interest	O
in	O
high	O
performers	O
and	O
low	O
performers	O
.	O

There	O
were	O
significantly	O
more	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
positive	O
cells	O
counted	O
in	O
the	O
nucleus	O
accumbens	O
core	O
of	O
high	O
performers	O
compared	O
to	O
low	O
performers	O
.	O

(*	O
p	O
<	O
0	O
.	O
05	O
)	O

Photomicrographs	O
of	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
staining	O
in	O
each	O
region	O
of	O
interest	O
,	O
showing	O
representative	O
low	O
performer	O
(	O
left	O
column	O
)	O
and	O
high	O
performer	O
(	O
right	O
column	O
).	O

All	O
images	O
were	O
taken	O
at	O
10	O
×	O
magnification	O
.	O

Discussion	O

The	O
present	O
studies	O
investigated	O
the	O
effects	O
of	O
several	O
manipulations	O
using	O
a	O
concurrent	O
PROG	O
/	O
chow	O
feeding	O
task	O
.	O

Experiment	O
1	O
demonstrated	O
that	O
the	O
DA	O
D2	B-GP
antagonist	O
haloperidol	O
decreased	O
number	O
of	O
lever	O
presses	O
,	O
maximum	O
ratio	O
achieved	O
,	O
and	O
active	O
lever	O
time	O
(	O
i	O
.	O
e	O
.,	O
the	O
time	O
the	O
PROG	O
schedule	O
was	O
active	O
).	O

These	O
findings	O
are	O
consistent	O
with	O
previous	O
studies	O
showing	O
the	O
ability	O
of	O
DA	O
antagonists	O
or	O
accumbens	O
DA	O
depletions	O
to	O
reduce	O
food	O
-	O
reinforced	O
lever	O
pressing	O
in	O
animals	B-OG
responding	O
on	O
the	O
concurrent	O
FR5	O
/	O
choice	O
task	O
[	O
6	O
],	O
[	O
25	O
],	O
[	O
30	O
],	O
as	O
well	O
as	O
conventional	O
operant	O
schedules	O
,	O
including	O
various	O
versions	O
of	O
the	O
progressive	O
ratio	O
schedule	O
[	O
52	O
],	O
[	O
53	O
].	O

Moreover	O
,	O
they	O
are	O
consistent	O
with	O
recent	O
research	O
showing	O
that	O
the	O
increased	O
DA	O
transmission	O
resulting	O
from	O
DA	B-GP
transporter	I-GP
knockdown	O
enhanced	O
progressive	O
ratio	O
performance	O
,	O
including	O
conditions	O
in	O
which	O
a	O
PROG	O
schedule	O
reinforced	O
by	O
sucrose	O
was	O
available	O
in	O
the	O
home	O
cage	O
and	O
non	O
-	O
deprived	O
animals	B-OG
also	O
had	O
their	O
homecage	O
food	O
available	O
[	O
13	O
].	O

Despite	O
producing	O
clear	O
reductions	O
in	O
measures	O
of	O
operant	O
responding	O
,	O
haloperidol	O
did	O
not	O
decrease	O
chow	O
intake	O
,	O
which	O
indicates	O
that	O
primary	O
food	O
motivation	O
was	O
intact	O
in	O
haloperidol	O
-	O
treated	O
rats	B-OG
.	O

Moreover	O
,	O
previous	O
studies	O
have	O
shown	O
that	O
0	O
.	O
1	O
mg	O
/	O
kg	O
haloperidol	O
does	O
not	O
change	O
preference	O
for	O
these	O
specific	O
high	O
carbohydrate	O
food	O
pellets	O
relative	O
to	O
chow	O
,	O
or	O
reduce	O
total	O
intake	O
of	O
either	O
food	O
type	O
in	O
free	O
-	O
feeding	O
tests	O
[	O
6	O
],	O
[	O
54	O
].	O

In	O
fact	O
,	O
there	O
was	O
a	O
slight	O
tendency	O
for	O
some	O
rats	B-OG
to	O
show	O
increased	O
chow	O
intake	O
after	O
haloperidol	O
treatment	O
,	O
which	O
was	O
marked	O
by	O
the	O
significant	O
correlation	O
between	O
vehicle	O
lever	O
pressing	O
and	O
the	O
difference	O
in	O
chow	O
intake	O
between	O
vehicle	O
and	O
the	O
highest	O
dose	O
of	O
haloperidol	O
.	O

In	O
other	O
words	O
,	O
animals	B-OG
that	O
were	O
high	O
lever	O
press	O
responders	O
under	O
the	O
vehicle	O
condition	O
,	O
and	O
therefore	O
had	O
correspondingly	O
low	O
levels	O
of	O
chow	O
intake	O
,	O
showed	O
greater	O
increases	O
in	O
chow	O
consumption	O
on	O
haloperidol	O
than	O
low	O
responders	O
did	O
.	O

In	O
fact	O
,	O
the	O
4	O
rats	B-OG
with	O
the	O
highest	O
level	O
of	O
lever	O
pressing	O
showed	O
very	O
substantial	O
increases	O
in	O
chow	O
intake	O
after	O
haloperidol	O
injection	O
(	O
i	O
.	O
e	O
.,	O
increases	O
of	O
3	O
–	O
6	O
grams	O
relative	O
to	O
vehicle	O
).	O

Nevertheless	O
,	O
unlike	O
the	O
previous	O
experiments	O
using	O
the	O
FR5	O
/	O
chow	O
choice	O
task	O
[	O
6	O
],	O
[	O
25	O
],	O
[	O
30	O
],	O
haloperidol	O
did	O
not	O
produce	O
an	O
overall	O
significant	O
increase	O
in	O
chow	O
intake	O
.	O

One	O
possible	O
explanation	O
for	O
this	O
pattern	O
is	O
the	O
different	O
levels	O
of	O
chow	O
intake	O
with	O
the	O
two	O
procedures	O
.	O

With	O
the	O
FR5	O
/	O
chow	O
choice	O
procedure	O
,	O
baseline	O
or	O
control	O
levels	O
of	O
lever	O
pressing	O
are	O
relatively	O
high	O
,	O
while	O
chow	O
intake	O
is	O
relatively	O
low	O
(	O
i	O
.	O
e	O
.,	O
1	O
–	O
2	O
grams	O
),	O
making	O
it	O
possible	O
to	O
observe	O
an	O
increase	O
in	O
chow	O
intake	O
with	O
administration	O
of	O
a	O
DA	O
antagonist	O
.	O

In	O
contrast	O
,	O
baseline	O
or	O
control	O
levels	O
of	O
chow	O
intake	O
are	O
much	O
higher	O
with	O
the	O
PROG	O
/	O
chow	O
choice	O
procedure	O
(	O
i	O
.	O
e	O
.,	O
7	O
–	O
8	O
grams	O
),	O
and	O
are	O
near	O
ceiling	O
levels	O
of	O
chow	O
intake	O
for	O
a	O
30	O
minute	O
period	O
without	O
water	O
being	O
available	O
.	O

For	O
example	O
,	O
Randall	O
et	O
al	O
.	O
[	O
50	O
]	O
demonstrated	O
that	O
food	O
-	O
restricted	O
rats	B-OG
in	O
a	O
free	O
feeding	O
study	O
consume	O
approximately	O
8	O
grams	O
of	O
chow	O
in	O
a	O
30	O
-	O
minute	O
period	O
.	O

Thus	O
,	O
with	O
the	O
PROG	O
/	O
chow	O
choice	O
procedure	O
,	O
it	O
is	O
difficult	O
to	O
observe	O
drug	O
-	O
induced	O
increases	O
in	O
chow	O
intake	O
in	O
animals	B-OG
that	O
are	O
already	O
eating	O
chow	O
at	O
maximal	O
or	O
near	O
maximal	O
levels	O
.	O

Nevertheless	O
,	O
compared	O
to	O
the	O
FR5	O
/	O
chow	O
choice	O
procedure	O
,	O
the	O
PROG	O
/	O
chow	O
choice	O
task	O
is	O
better	O
suited	O
for	O
observing	O
large	O
reductions	O
in	O
chow	O
intake	O
due	O
to	O
appetite	O
-	O
related	O
manipulations	O
such	O
as	O
pre	O
-	O
feeding	O
or	O
appetite	O
suppressant	O
drugs	O
(	O
see	O
discussion	O
below	O
).	O

The	O
adenosine	B-GP
A2A	I-GP
antagonist	O
MSX	O
-	O
3	O
produced	O
effects	O
that	O
were	O
opposite	O
to	O
those	O
of	O
haloperidol	O
;	O
MSX	O
-	O
3	O
increased	O
number	O
of	O
lever	O
presses	O
and	O
maximum	O
ratio	O
achieved	O
,	O
and	O
also	O
increased	O
the	O
amount	O
of	O
time	O
that	O
animals	B-OG
kept	O
the	O
lever	O
active	O
during	O
the	O
session	O
.	O

This	O
is	O
consistent	O
with	O
previous	O
work	O
showing	O
that	O
adenosine	B-GP
A2A	I-GP
antagonists	O
have	O
stimulant	O
-	O
like	O
properties	O
.	O

For	O
example	O
,	O
the	O
adenosine	B-GP
A2A	I-GP
antagonists	O
MSX	O
-	O
3	O
and	O
istradefylline	O
increased	O
lever	O
pressing	O
on	O
a	O
fixed	O
interval	O
4	O
-	O
minute	O
schedule	O
,	O
which	O
generates	O
a	O
relatively	O
low	O
baseline	O
rate	O
of	O
responding	O
[	O
40	O
].	O

In	O
addition	O
,	O
the	O
PROG	O
/	O
chow	O
feeding	O
choice	O
procedure	O
allowed	O
for	O
parallel	O
assessment	O
of	O
food	O
intake	O
,	O
and	O
MSX	O
-	O
3	O
decreased	O
chow	O
consumption	O
at	O
the	O
highest	O
dose	O
.	O

Interestingly	O
,	O
although	O
MSX	O
-	O
3	O
and	O
haloperidol	O
produced	O
opposite	O
effects	O
on	O
measures	O
of	O
PROG	O
lever	O
pressing	O
and	O
chow	O
intake	O
,	O
in	O
both	O
experiments	O
,	O
the	O
reciprocal	O
relation	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
was	O
preserved	O
,	O
as	O
indicated	O
by	O
the	O
high	O
negative	O
correlations	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
across	O
all	O
treatments	O
(−	O
0	O
.	O
76	O
and	O
−	O
0	O
.	O
78	O
).	O

Significant	O
negative	O
partial	O
correlations	O
also	O
were	O
observed	O
in	O
the	O
haloperidol	O
and	O
MSX	O
-	O
3	O
experiments	O
when	O
partial	O
correlations	O
were	O
used	O
to	O
control	O
for	O
between	O
-	O
subject	O
variability	O
in	O
lever	O
pressing	O
.	O

This	O
inverse	O
correlation	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
has	O
been	O
reported	O
in	O
previous	O
experiments	O
studying	O
the	O
effects	O
of	O
DA	O
antagonists	O
or	O
depletions	O
on	O
FR5	O
/	O
chow	O
feeding	O
choice	O
performance	O
[	O
25	O
],	O
[	O
27	O
],	O
[	O
30	O
].	O

Experiment	O
3	O
was	O
conducted	O
to	O
determine	O
the	O
effect	O
of	O
appetite	O
-	O
related	O
manipulations	O
on	O
PROG	O
/	O
chow	O
feeding	O
choice	O
performance	O
,	O
in	O
order	O
to	O
provide	O
a	O
contrast	O
with	O
the	O
effects	O
of	O
haloperidol	O
.	O

Two	O
different	O
appetite	O
manipulations	O
were	O
employed	O
:	O
pre	O
-	O
feeding	O
,	O
and	O
administration	O
of	O
a	O
cannabinoid	O
CB1	B-GP
receptor	I-GP
antagonist	O
/	O
inverse	O
agonist	O
.	O

Pre	O
-	O
feeding	O
animals	B-OG
prior	O
to	O
their	O
test	O
session	O
,	O
which	O
was	O
used	O
to	O
reduce	O
food	O
motivation	O
and	O
thereby	O
devalue	O
the	O
food	O
reinforcement	O
[	O
15	O
],	O
[	O
54	O
],	O
produced	O
marked	O
decreases	O
in	O
number	O
of	O
lever	O
presses	O
and	O
highest	O
ratio	O
achieved	O
.	O

But	O
,	O
unlike	O
the	O
effects	O
of	O
haloperidol	O
,	O
pre	O
-	O
feeding	O
also	O
substantially	O
reduced	O
chow	O
consumption	O
.	O

In	O
experiment	O
3b	O
,	O
the	O
CB1	B-GP
receptor	I-GP
antagonist	O
/	O
inverse	O
agonist	O
AM251	O
was	O
assessed	O
.	O

CB1	B-GP
antagonists	O
/	O
inverse	O
agonists	O
are	O
putative	O
appetite	O
suppressant	O
drugs	O
that	O
have	O
been	O
shown	O
to	O
decrease	O
food	O
intake	O
in	O
animals	B-OG
[	O
30	O
],	O
[	O
49	O
],	O
[	O
50	O
],	O
[	O
55	O
]	O
and	O
humans	B-OG
[	O
56	O
].	O

Moreover	O
,	O
stimulation	O
of	O
CB1	B-GP
receptors	I-GP
in	O
nucleus	O
accumbens	O
shell	O
increased	O
hedonic	O
taste	O
reactivity	O
for	O
intraoral	O
sucrose	O
[	O
57	O
].	O

On	O
the	O
PROG	O
/	O
chow	O
feeding	O
choice	O
task	O
,	O
AM251	O
decreased	O
number	O
of	O
lever	O
presses	O
,	O
maximum	O
ratio	O
achieved	O
,	O
and	O
chow	O
consumption	O
.	O

Thus	O
,	O
the	O
pattern	O
of	O
effects	O
on	O
lever	O
pressing	O
and	O
chow	O
intake	O
produced	O
by	O
pre	O
-	O
feeding	O
and	O
AM251	O
differed	O
markedly	O
from	O
those	O
produced	O
by	O
haloperidol	O
.	O

Moreover	O
,	O
while	O
there	O
was	O
a	O
high	O
inverse	O
correlation	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
in	O
the	O
haloperidol	O
experiment	O
,	O
there	O
were	O
no	O
significant	O
correlations	O
or	O
partial	O
correlations	O
between	O
these	O
measures	O
in	O
the	O
pre	O
-	O
feeding	O
and	O
AM251	O
experiments	O
.	O

This	O
analysis	O
shows	O
that	O
the	O
inverse	O
relation	O
between	O
lever	O
pressing	O
and	O
chow	O
intake	O
,	O
which	O
is	O
evident	O
under	O
baseline	O
conditions	O
and	O
also	O
throughout	O
the	O
haloperidol	O
experiment	O
,	O
is	O
not	O
shown	O
when	O
primary	O
food	O
motivation	O
is	O
reduced	O
by	O
pre	O
-	O
feeding	O
or	O
drugs	O
,	O
because	O
appetite	O
-	O
suppressant	O
manipulations	O
decrease	O
both	O
food	O
reinforced	O
lever	O
pressing	O
and	O
chow	O
consumption	O
[	O
25	O
],	O
[	O
30	O
].	O

There	O
are	O
a	O
number	O
of	O
factors	O
that	O
can	O
influence	O
progressive	O
ratio	O
performance	O
[	O
58	O
],	O
and	O
rather	O
than	O
yielding	O
a	O
simple	O
measure	O
of	O
“	O
reward	O
”,	O
progressive	O
ratio	O
breakpoints	O
represent	O
the	O
outcome	O
of	O
a	O
cost	O
/	O
benefit	O
analysis	O
related	O
partially	O
to	O
characteristics	O
of	O
the	O
reinforcer	O
itself	O
,	O
but	O
also	O
the	O
work	O
-	O
related	O
response	O
costs	O
and	O
time	O
constraints	O
imposed	O
by	O
the	O
ratio	O
schedule	O
[	O
2	O
].	O

Indeed	O
,	O
previous	O
work	O
has	O
demonstrated	O
that	O
progressive	O
ratio	O
break	O
points	O
are	O
sensitive	O
to	O
work	O
-	O
related	O
factors	O
such	O
as	O
the	O
height	O
of	O
the	O
lever	O
[	O
59	O
].	O

Taken	O
together	O
,	O
experiments	O
1	O
–	O
3	O
demonstrate	O
that	O
it	O
is	O
exceedingly	O
unlikely	O
that	O
haloperidol	O
is	O
decreasing	O
PROG	O
lever	O
pressing	O
because	O
of	O
a	O
reduction	O
in	O
primary	O
food	O
motivation	O
,	O
appetite	O
,	O
or	O
the	O
unconditioned	O
reinforcing	O
properties	O
of	O
food	O
.	O

Clearly	O
,	O
in	O
the	O
absence	O
of	O
parallel	O
measures	O
of	O
food	O
intake	O
,	O
or	O
taste	O
reactivity	O
[	O
57	O
],	O
[	O
60	O
],	O
progressive	O
ratio	O
break	O
points	O
should	O
not	O
be	O
used	O
as	O
markers	O
of	O
food	O
“	O
reward	O
”,	O
or	O
“	O
hedonic	O
”	O
reactivity	O
to	O
food	O
[	O
61	O
].	O

Rather	O
,	O
they	O
provide	O
a	O
measure	O
of	O
how	O
much	O
work	O
the	O
organism	O
will	O
do	O
in	O
order	O
to	O
gain	O
access	O
to	O
a	O
reinforcing	O
stimulus	O
[	O
2	O
],	O
[	O
61	O
],	O
[	O
62	O
].	O

An	O
important	O
aspect	O
of	O
the	O
PROG	O
/	O
choice	O
procedure	O
is	O
that	O
performance	O
is	O
characterized	O
by	O
substantial	O
individual	O
variability	O
.	O

While	O
some	O
rats	B-OG
lever	O
pressed	O
relatively	O
little	O
and	O
had	O
high	O
levels	O
of	O
chow	O
intake	O
,	O
others	O
lever	O
pressed	O
much	O
more	O
and	O
ate	O
relatively	O
little	O
chow	O
.	O

Experiment	O
4	O
employed	O
pDARPP	O
-	O
32	O
-(	O
Thr34	O
)	O
immunohistochemistry	O
to	O
determine	O
if	O
there	O
were	O
neurochemical	O
differences	O
between	O
high	O
responders	O
and	O
low	O
responders	O
.	O

The	O
entire	O
group	O
of	O
animals	B-OG
was	O
divided	O
in	O
two	O
by	O
a	O
median	O
split	O
based	O
upon	O
numbers	O
of	O
lever	O
presses	O
,	O
and	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
was	O
determined	O
.	O

High	O
responders	O
did	O
not	O
differ	O
from	O
low	O
responders	O
in	O
terms	O
of	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
in	O
CG1	O
or	O
CG2	O
regions	O
of	O
anterior	O
cingulate	O
cortex	O
.	O

In	O
the	O
accumbens	O
shell	O
,	O
there	O
was	O
a	O
slight	O
tendency	O
for	O
high	O
responders	O
to	O
show	O
increased	O
pDARPP	O
-	O
32	O
expression	O
,	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
.	O

However	O
,	O
high	O
responders	O
did	O
show	O
significantly	O
greater	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
in	O
accumbens	O
core	O
than	O
low	O
responders	O
.	O

pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
immunoreactivity	O
was	O
used	O
to	O
provide	O
a	O
marker	O
of	O
signal	O
transduction	O
activity	O
,	O
and	O
evidence	O
indicates	O
that	O
DA	O
acting	O
through	O
the	O
D1	B-GP
receptor	I-GP
and	O
related	O
G	B-GP
proteins	I-GP
(	O
Gs	B-GP
/	O
Golf	B-GP
)	O
activates	O
adenylate	B-GP
cyclase	I-GP
activity	O
,	O
thereby	O
stimulating	O
PKA	B-GP
-	O
mediated	O
phosphorylation	O
of	O
DARPP	B-GP
-	I-GP
32	I-GP
at	O
the	O
Thr34	O
site	O
[	O
45	O
]–[	O
48	O
].	O

DARPP	B-GP
-	I-GP
32	I-GP
expression	O
has	O
been	O
used	O
to	O
study	O
drug	O
effects	O
[	O
47	O
],	O
[	O
48	O
],	O
and	O
a	O
few	O
studies	O
have	O
focused	O
on	O
changes	O
in	O
DARPP	B-GP
-	I-GP
32	I-GP
immunoreactivity	O
associated	O
with	O
behavioral	O
manipulations	O
.	O

Danielli	O
et	O
al	O
.	O
[	O
63	O
]	O
demonstrated	O
that	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
showed	O
increased	O
expression	O
in	O
nucleus	O
accumbens	O
shell	O
after	O
the	O
first	O
exposure	O
to	O
a	O
novel	O
food	O
.	O

Recently	O
,	O
Segovia	O
et	O
al	O
.	O
[	O
44	O
]	O
reported	O
that	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
in	O
accumbens	O
shell	O
and	O
core	O
was	O
increased	O
in	O
animals	B-OG
undergoing	O
FR5	O
operant	O
training	O
.	O

Although	O
several	O
neurochemical	O
factors	O
can	O
influence	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
production	O
[	O
48	O
],	O
it	O
is	O
reasonable	O
to	O
suggest	O
that	O
the	O
higher	O
level	O
of	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
in	O
high	O
responders	O
relative	O
to	O
low	O
responders	O
could	O
reflect	O
greater	O
DA	O
release	O
in	O
the	O
animals	B-OG
working	O
harder	O
on	O
the	O
lever	O
pressing	O
component	O
of	O
the	O
task	O
[	O
44	O
],	O
[	O
64	O
].	O

If	O
so	O
,	O
this	O
could	O
indicate	O
that	O
individual	O
differences	O
in	O
work	O
output	O
are	O
related	O
to	O
individual	O
differences	O
in	O
DA	O
transmission	O
in	O
striatal	O
areas	O
,	O
as	O
recently	O
shown	O
in	O
a	O
human	B-OG
imaging	O
study	O
[	O
65	O
].	O

Furthermore	O
,	O
these	O
observations	O
of	O
individual	O
variability	O
in	O
exertion	O
of	O
physical	O
effort	O
are	O
consistent	O
with	O
recent	O
studies	O
of	O
individual	O
variability	O
in	O
cognitive	O
effort	O
across	O
subjects	O
(	O
i	O
.	O
e	O
.,	O
“	O
workers	O
”	O
vs	O
.	O
“	O
slackers	O
”)	O
[	O
66	O
].	O

Conclusions	O

In	O
summary	O
,	O
the	O
DA	O
antagonist	O
haloperidol	O
reduced	O
the	O
number	O
of	O
lever	O
presses	O
and	O
highest	O
ratio	O
achieved	O
but	O
did	O
not	O
suppress	O
chow	O
intake	O
.	O

In	O
contrast	O
,	O
the	O
adenosine	B-GP
A2A	I-GP
antagonist	O
MSX	O
-	O
3	O
increased	O
lever	O
presses	O
and	O
highest	O
ratio	O
achieved	O
,	O
but	O
decreased	O
chow	O
consumption	O
.	O

Pre	O
-	O
feeding	O
and	O
administration	O
of	O
the	O
cannabinoid	O
CB1	B-GP
antagonist	O
/	O
inverse	O
agonist	O
AM251	O
decreased	O
lever	O
presses	O
,	O
highest	O
ratio	O
achieved	O
,	O
and	O
chow	O
intake	O
.	O

Including	O
the	O
option	O
of	O
having	O
chow	O
concurrently	O
available	O
allows	O
one	O
to	O
conclude	O
that	O
the	O
effects	O
of	O
DA	O
antagonism	O
differed	O
greatly	O
from	O
those	O
produced	O
by	O
pre	O
-	O
feeding	O
or	O
decreases	O
in	O
CB1	B-GP
transmission	O
,	O
despite	O
the	O
fact	O
that	O
all	O
three	O
manipulations	O
decreased	O
lever	O
pressing	O
.	O

Thus	O
,	O
haloperidol	O
is	O
not	O
reducing	O
PROG	O
responding	O
because	O
of	O
a	O
general	O
reduction	O
in	O
primary	O
food	O
motivation	O
or	O
the	O
valuation	O
of	O
food	O
reinforcement	O
.	O

Instead	O
,	O
the	O
present	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
haloperidol	O
left	O
aspects	O
of	O
food	O
motivation	O
intact	O
,	O
but	O
reduced	O
the	O
tendency	O
to	O
work	O
for	O
food	O
reinforcement	O
.	O

Furthermore	O
,	O
DA	O
-	O
related	O
signal	O
transduction	O
activity	O
(	O
pDARPP	O
-	O
32	O
(	O
Thr34	O
)	O
expression	O
)	O
was	O
greater	O
in	O
high	O
responders	O
(	O
i	O
.	O
e	O
.,	O
rats	B-OG
with	O
high	O
lever	O
pressing	O
output	O
)	O
compared	O
to	O
low	O
responders	O
,	O
indicating	O
that	O
accumbens	O
core	O
signal	O
transduction	O
activity	O
is	O
related	O
to	O
individual	O
differences	O
in	O
work	O
output	O
.	O

Future	O
studies	O
should	O
compare	O
the	O
effects	O
of	O
DA	O
D1	B-GP
and	O
D2	B-GP
antagonists	O
,	O
and	O
should	O
determine	O
if	O
adenosine	B-GP
A2A	I-GP
antagonism	O
is	O
capable	O
of	O
reversing	O
the	O
effects	O
of	O
DA	O
antagonism	O
.	O

Studies	O
comparing	O
cannabinoid	O
CB1	B-GP
inverse	O
agonists	O
with	O
neutral	O
antagonists	O
(	O
e	O
.	O
g	O
.	O
50	O
,	O
30	O
)	O
would	O
be	O
useful	O
for	O
further	O
exploration	O
of	O
the	O
role	O
of	O
CB1	B-GP
receptor	I-GP
signaling	O
in	O
performance	O
on	O
this	O
procedure	O
.	O

Finally	O
,	O
additional	O
neurochemical	O
measures	O
should	O
be	O
investigated	O
for	O
their	O
possible	O
relation	O
to	O
lever	O
pressing	O
output	O
on	O
this	O
task	O
,	O
including	O
microdialysis	O
studies	O
of	O
DA	O
release	O
[	O
64	O
],	O
and	O
other	O
markers	O
of	O
signal	O
transduction	O
activity	O
(	O
e	O
.	O
g	O
.	O
c	B-GP
-	I-GP
Fos	I-GP
,	O
pDARPP	O
-	O
32	O
(	O
Thr75	O
))	O
in	O
different	O
striatal	O
cell	O
types	O
(	O
e	O
.	O
g	O
.	O
encephalin	B-GP
or	O
substance	B-GP
P	I-GP
positive	O
neurons	O
;	O
[	O
44	O
]).	O

These	O
studies	O
are	O
important	O
for	O
understanding	O
activational	O
aspects	O
of	O
motivation	O
,	O
and	O
may	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
neural	O
basis	O
of	O
effort	O
-	O
related	O
motivational	O
impairments	O
(	O
e	O
.	O
g	O
.	O
anergia	O
,	O
psychomotor	O
retardation	O
,	O
fatigue	O
)	O
in	O
depression	B-DS
and	O
other	O
disorders	O
[	O
1	O
],	O
[	O
2	O
],	O
[	O
67	O
].	O

